Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 2,154 shares, an increase of ∞ from the June 15th total of 0 shares. Based on an average trading volume of 101,921 shares, the short-interest ratio is currently 0.0 days.
Ono Pharmaceutical Trading Down 2.2%
OTCMKTS OPHLY opened at $4.87 on Thursday. Ono Pharmaceutical has a 1 year low of $3.52 and a 1 year high of $5.75. The company’s 50 day simple moving average is $4.89 and its two-hundred day simple moving average is $4.99.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
